New pill shows promise in early trial for Hard-to-Treat cancers
NCT ID NCT06212076
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new drug called IPG1094 in 60 people with advanced solid tumors that cannot be removed by surgery. The drug works by blocking a protein called MIF, which may help slow cancer growth. The trial has two parts: first, finding the safest dose, then seeing if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPG1094 (a MIF inhibitor tablet)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early phase 1/2 trial with only 60 participants, so it is too soon to know if IPG1094 is safe or effective. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••